Published in N Engl J Med on December 23, 1999
Non-eosinophilic asthma: importance and possible mechanisms. Thorax (2002) 3.53
New insights into the pathogenesis of asthma. J Clin Invest (2003) 2.66
Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 1.94
Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol (2015) 1.70
The role of allergy in severe asthma. Clin Exp Allergy (2012) 1.54
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol (2014) 1.47
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy (2014) 1.29
JAK-STAT signaling in asthma. J Clin Invest (2002) 1.17
Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors. J Clin Invest (2003) 1.16
Airway remodelling in asthma: from benchside to clinical practice. Can Respir J (2010) 1.11
Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol (2008) 1.10
Peanut allergy: an overview. CMAJ (2003) 1.06
Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci U S A (2005) 1.03
T cell directives for transcriptional regulation in asthma. Springer Semin Immunopathol (2003) 0.98
[Ocular allergies]. Ophthalmologe (2005) 0.94
Conformational flexibility in immunoglobulin E-Fc 3-4 revealed in multiple crystal forms. J Mol Biol (2009) 0.94
Lymphotoxin is required for maintaining physiological levels of serum IgE that minimizes Th1-mediated airway inflammation. J Exp Med (2003) 0.94
Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol (2009) 0.92
Environmental contributions to the allergic asthma epidemic. Environ Health Perspect (2002) 0.90
Chronic allergen challenge induces bronchial mast cell accumulation in BALB/c but not C57BL/6 mice and is independent of IL-9. Immunogenetics (2010) 0.88
Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics. Lipids Health Dis (2013) 0.86
Corticosteroids, IgE, and atopy. J Clin Invest (2001) 0.85
Current and future applications of the anti-IgE antibody omalizumab. Biologics (2008) 0.85
IgE actions on CD4+ T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms. EMBO Mol Med (2014) 0.85
How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol (2009) 0.84
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med (2000) 0.83
Allergy and the lung. Clin Exp Immunol (2008) 0.83
Clinically useful monoclonal antibodies in treatment. J Clin Pathol (2002) 0.82
Omalizumab: a monoclonal anti-IgE antibody. MedGenMed (2005) 0.82
Suppression of IgE B cells and IgE binding to Fc(epsilon)RI by gene therapy with single-chain anti-IgE. J Immunol (2009) 0.82
Pharmacotherapy of severe asthma. Curr Opin Pharmacol (2010) 0.81
The role of omalizumab in the treatment of severe allergic asthma. Can Respir J (2006) 0.81
New insights into basophil heterogeneity. Semin Immunopathol (2016) 0.81
Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A. J Invest Dermatol (2013) 0.80
Severe asthma and the omalizumab option. Clin Mol Allergy (2008) 0.80
Asthma Was Talking, But We Weren't Listening. Missed or Ignored Signals That Have Slowed Treatment Progress. Ann Am Thorac Soc (2016) 0.79
Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children. Allergy (2014) 0.79
Relationships between total and allergen-specific serum IgE concentrations and lung function in young adults. Ann Allergy Asthma Immunol (2012) 0.78
Prevention strategies for asthma--secondary prevention. CMAJ (2005) 0.78
Anti-IgE antibody therapy for asthma. N Engl J Med (1999) 0.78
Perinatal gene-gene and gene-environment interactions on IgE production and asthma development. Clin Dev Immunol (2012) 0.77
Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation. Postepy Dermatol Alergol (2014) 0.76
Biologic modulators in allergic and autoinflammatory diseases. Curr Opin Allergy Clin Immunol (2011) 0.76
Immunotherapy in food allergy. Immunotherapy (2010) 0.76
Immunotherapy. CMAJ (2005) 0.76
Omalizumab: the evidence for its place in the treatment of allergic asthma. Core Evid (2008) 0.76
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics (2017) 0.75
Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Ther Adv Chronic Dis (2017) 0.75
Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both? Open Allergy J (2010) 0.75
What have transgenic and knockout animals taught us about respiratory disease? Respir Res (2000) 0.75
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. Case Rep Dermatol (2017) 0.75
Unusual asthma syndromes and their management. Ther Adv Chronic Dis (2011) 0.75
Biologic therapies: what and when? J Clin Pathol (2007) 0.75
Is there a role for treatment of asthma with omalizumab? Arch Dis Child (2003) 0.75
Molecular mechanisms of atopy. Mediators Inflamm (2001) 0.75
Recent advances: Respiratory medicine. BMJ (2001) 0.75
Blocking of Histamine Release and IgE Binding to FcεRI on Human Basophils by Antibodies Produced in Camels. Allergy Asthma Immunol Res (2015) 0.75
Life-threatening allergic bronchopulomnary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody. J R Soc Med (2009) 0.75
Asthma and therapeutics: recombinant therapies in asthma. Allergy Asthma Clin Immunol (2005) 0.75
CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids. Inflamm Res (2002) 0.75
Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. Ophthalmol Ther (2016) 0.75
Ragweed immunotherapy in adult asthma. N Engl J Med (1996) 4.69
The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol (2000) 4.53
Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. J Allergy Clin Immunol (1988) 3.57
Identification of a Brazil-nut allergen in transgenic soybeans. N Engl J Med (1996) 2.41
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med (1997) 2.28
Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis (1990) 2.02
DNA antisense therapy for asthma in an animal model. Nature (1997) 1.91
Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am Rev Respir Dis (1987) 1.91
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest (1998) 1.75
Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect Immun (1997) 1.72
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med (1997) 1.71
Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest (1981) 1.57
Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation. Chest (1986) 1.53
The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med (1994) 1.44
Radiation therapy for diabetes insipidus caused by Langerhans cell histiocytosis. Int J Radiat Oncol Biol Phys (1992) 1.41
Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun (1993) 1.40
Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J Immunol (1997) 1.38
Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis (1992) 1.33
Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J Immunol (1998) 1.31
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol (1997) 1.29
Analysis of repeated markers used to predict progression of cancer. Stat Med (1998) 1.26
Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol (1996) 1.25
Thyroid disease and asthma. J Allergy Clin Immunol (1977) 1.25
IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis (1985) 1.25
Cystic fibrosis. J Clin Invest (1987) 1.24
Campylobacter fetus septic arthritis: report of a case. Yale J Biol Med (1979) 1.24
Sauna-takers disease. Hypersensitivity pneumonitis due to contaminated water in a home sauna. JAMA (1976) 1.20
Sulfites in foods: uses, analytical methods, residues, fate, exposure assessment, metabolism, toxicity, and hypersensitivity. Adv Food Res (1986) 1.20
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol (1994) 1.18
Bronchoalveolar lavage. Thorax (1980) 1.18
The safety of immunotherapy during pregnancy. J Allergy Clin Immunol (1978) 1.18
Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels. Arch Intern Med (1978) 1.18
Late asthmatic responses: inquiry into mechanisms and significance. Clin Rev Allergy (1985) 1.18
Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res (1986) 1.17
Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor. J Pharmacol Exp Ther (1994) 1.12
Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies. J Immunol Methods (1980) 1.12
Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest (1987) 1.10
Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol (1994) 1.10
Environmental allergen avoidance: an overview. J Allergy Clin Immunol (2001) 1.10
In vitro production of IgE by human peripheral blood lymphocytes: effect of cholera toxin and beta adrenergic stimulation. J Immunol (1976) 1.09
Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res (1993) 1.08
The requirement for platelets in allergen-induced late asthmatic airway obstruction. Eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis (1990) 1.03
Immunology of a serum sickness/vasculitis reaction secondary to streptokinase used for acute myocardial infarction. Clin Exp Rheumatol (1989) 1.02
Prevalence of bronchial hyperresponsiveness in highly trained athletes. Chest (1986) 1.01
Soybean oil is not allergenic to soybean-sensitive individuals. J Allergy Clin Immunol (1985) 1.00
Quantifying the clinical significance of drug-drug interactions: scaling pharmacists' perceptions of a common interaction classification scheme. Ann Pharmacother (1996) 0.99
Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol (1994) 0.98
Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am Rev Respir Dis (1986) 0.97
A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much? Clin Exp Allergy (2004) 0.96
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1999) 0.96
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer (1994) 0.95
Effects of experimental rhinovirus 16 infection on airways and leukocyte function in normal subjects. J Allergy Clin Immunol (1978) 0.95
A novel marine bacterium algicidal to the toxic dinoflagellate Alexandrium tamarense. Lett Appl Microbiol (2010) 0.95
A critical evaluation of clinical trials in reactions to sulfites. J Allergy Clin Immunol (1986) 0.95
Amplification of the enzyme-linked immunosorbent assay for measuring allergen-specific IgE and IgG antibody. Clin Allergy (1981) 0.94
Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol (1990) 0.94
The laboratory evaluation of IgE antibody to metabisulfites in patients skin test positive to metabisulfites. J Allergy Clin Immunol (1988) 0.94
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol (1994) 0.94
A review of Alternaria alternata sensitivity. Rev Iberoam Micol (2001) 0.94
Economic impact of cost-containment strategies in third party programmes in the US (part I). Pharmacoeconomics (1993) 0.93
Generation and partial characterization of eosinophil chemotactic activity and neutrophil chemotactic activity during early and late-phase asthmatic response. J Allergy Clin Immunol (1986) 0.93
Alterations in the antibacterial properties of rabbit pulmonary macrophages exposed to wood smoke. Am Rev Respir Dis (1984) 0.92
Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med (1999) 0.92
Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J Allergy Clin Immunol (1999) 0.92
Biologic activity of purified cotton bract extracts in man and guinea pig. Environ Health Perspect (1986) 0.91
Prevalence of sensitivity to sulfiting agents in asthmatic patients. Am J Med (1986) 0.91
Serious adverse reactions to protamine sulfate: are alternatives needed? J Allergy Clin Immunol (1985) 0.91
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol (1994) 0.91
Food allergens: structure and immunologic properties. Ann Allergy (1987) 0.90
Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase. J Lab Clin Med (1989) 0.90
Increased bronchovascular permeability after allergen exposure in sensitive asthmatics. J Appl Physiol (1985) (1987) 0.90
Allergic reaction to latex: a risk factor for unsuspected anaphylaxis. Allergy Proc (1991) 0.90
Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol (1988) 0.89
Independent mutations in the flanking sequence of the alpha-1-antitrypsin gene are associated with chronic obstructive airways disease. Dis Markers (1991) 0.89
Adverse reaction to lupine-fortified pasta. J Allergy Clin Immunol (1994) 0.89
Hypersensitivity lung disease: early diagnosis. J Allergy Clin Immunol (1978) 0.88
Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol (1989) 0.88
Airway adherence of Pseudomonas aeruginosa: mucoexopolysaccharide binding to human and bovine airway proteins. J Lab Clin Med (1991) 0.87
Occupationally acquired vibratory angioedema with secondary carpal tunnel syndrome. Ann Intern Med (1983) 0.87
Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. Am J Physiol (1994) 0.87
Comparison of morning and evening dosing with a 24-hour sustained-release theophylline, Uniphyl, for nocturnal asthma. Am J Med (1985) 0.87
IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol (1999) 0.86
The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion. J Clin Invest (1990) 0.86
Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis. Ann Pharmacother (2000) 0.86
Upper airway obstruction presenting as exercise-induced asthma. Chest (1984) 0.85
Evaluation of symptom relief, nasal airflow, nasal cytology, and acceptability of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. Ann Allergy (1990) 0.85
Use of ipratropium bromide in asthma. Results of a multi-clinic study. Am J Med (1986) 0.85
Nasal pathology and ultrastructure in patients with chronic airway inflammation (RADS and RUDS) following an irritant exposure. J Toxicol Clin Toxicol (1996) 0.85
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer (1992) 0.85
Demonstration of a free elastolytic metalloenzyme in human lung lavage fluid and its relationship to alpha 1-antiprotease. Am Rev Respir Dis (1984) 0.85
Bronchial challenge with adenosine causes the release of serum neutrophil chemotactic factor in asthma. Am Rev Respir Dis (1991) 0.84
Pseudomonas aeruginosa and the airways disease of cystic fibrosis. Clin Chest Med (1988) 0.84
Enhanced reactive oxygen species metabolism of airspace cells and airway inflammation follow antigen challenge in human asthma. J Allergy Clin Immunol (1990) 0.84
Antibody to multiple mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, measured by an enzyme-linked immunosorbent assay. Pediatr Res (1986) 0.83
Chronic rhinitis: an underrecognized association with fibromyalgia. Allergy Proc (1993) 0.83